Table 5.
Adverse events of concurrent chemoradiotherapy in previously reported phase II/III randomized controlled trials
| Study | CRT regimen | Leukopenia (%) | Neutropenia (%) | Thrombocytopenia (%) | Anemia (%) | Radiation pneumonitis (%) | Radiation esophagitis (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | ≥3 | All | ≥3 | All | ≥3 | All | ≥3 | All | ≥3 | All | ≥3 | ||
| RTOG 9410 [5] | RT + VP | NR | 83.9 | NR | NR | NR | 9.3 | NR | 11.8 | NR | 12.5 | NR | 22.2 |
| RT + EP | NR | 68.4 | NR | NR | NR | 16.0 | NR | 18.8 | NR | 16.9 | NR | 44.9 | |
| RTOG 0617 [41] | LDR + PC | 61.1 | 32.1 | 40.4 | 23.8 | 37.7 | 6.6 | 58.9 | 7.9 | 10.0 | 4.6 | 46.4 | 7.3 |
| HDR + PC | 57.0 | 30.8 | 46.7 | 26.2 | 41.1 | 7.5 | 58.9 | 8.0 | 12.1 | 1.0 | 54.2 | 15.0 | |
| LDR + PC + Cet | 51.8 | 30.7 | 54.7 | 40.9 | 35.8 | 8.0 | 63.4 | 11.6 | 12.4 | 7.3 | 43.8 | 6.6 | |
| HDR + PC + Cet | 54.0 | 37.0 | 59.0 | 46.9 | 44.0 | 16.0 | 51.0 | 6.0 | 17.0 | 6.0 | 54.0 | 19.0 | |
| PROCLAIM [42] | RT + PP | 36.7 | 22.6 | 42.8 | 24.4 | 55.0 | 40.3 | 40.3 | 8.8 | 17.0 | 1.8 | 48.1 | 15.5 |
| RT + EP | 40.8 | 30.1 | 54.8 | 44.5 | 85.0 | 29.0 | 45.6 | 13.6 | 10.7 | 2.6 | 50.7 | 20.6 | |
| CAMS [43] |
RT + EP RT + PC |
95.8 92.7 |
30.5 20.7 |
NR NR |
NR NR |
12.7 5.2 |
0 0 |
24.2 13.5 |
0 0 |
76.8 72.9 |
7.4 8.3 |
87.0 84.0 |
20.0 6.3 |
| WJOG5008L [44] | RT + SP | 96.3 | 40.7 | 88.9 | 33.3 | 42.6 | 9.3 | 79.6 | 25.5 | 24.1 | 9.3 | 66.7 | 3.7 |
| RT + VP | 100 | 79.6 | 94.4 | 75.9 | 22.0 | 3.7 | 88.9 | 27.8 | 20.4 | 7.4 | 74.1 | 0.0 | |
CRT Chemoradiotherapy, RT Radiotherapy, LDR Low dose radiation, HDR High dose radiation, VP Vinblastine plus cisplatin, EP Etoposide plus cisplatin, PC Paclitaxel plus carboplatin, Cet Cetuximab, PP Pemetrexed plus cisplatin, SP S1 plus cisplatin, NR Not reported